

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 4 |
|-------|---|----|---|

Complete if Known

| | |
|-------------------------------|----------------------------|
| Application Number | 10/643,743 |
| Filing Date | August 19, 2003 |
| First Named Inventor | Réal Lemieux et al. |
| Art Unit | 1645 |
| Examiner Name | Not yet known |
| Attorney Docket Number | 701826-054340 |

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

Date
Considered

9127106


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|---------------|
| Substitute for form 1449PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/643,743 | | |
| | | Filing Date | August 19, 2003 | | |
| | | First Named Inventor | Réal Lemieux et al. | | |
| | | Art Unit | 1645 | | |
| | | Examiner Name | Not yet known | | |
| Sheet | 2 | of | 4 | Attorney Docket Number | 701826-054340 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| B1 | C1 | Adib M, Ragimbeau J, Avrameas S, Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol. 1990;145:3807-3813 | |
| | C2 | Avrameas S, Ternynck T. The natural autoantibodies system: between hypotheses and facts. Mol Immunol. 1993;30:1133-1142 | |
| | C3 | Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc. 2002;42:449-459 | |
| | C4 | Berneman A, Guilbert B, Eschrich S, Avrameas S. IgG auto- and polyreactivities of normal human sera. Mol Immunol. 1993;30:1499-1510 | |
| B5 | C5 | Dahl MV, Bridges AG. Intravenous immune globulin: fighting antibodies with antibodies. J Am Acad Dermatol. 2001;45:775-783 | |
| | C6 | Dietrich G, Algiman M, Y S, Nydegger UE, Kazatchkine MD. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood. 1992;79:2946-2951 | |
| | C7 | Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, Spaeth PJ, Neftel KA. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol. 2001;68:4-10 | |
| | C8 | Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenia purpura by high-dose intravenous gamma globulin. N Eng J Med. 1982;306:1254-1258 | |
| | C9 | Hadley AG, Kumpel BM, Merry AH. The chemiluminescent response of human monocytes to red cells sensitized with monoclonal anti-Rh(D) antibodies. Clin Lab Haematol. 1988;10:377-384 | |
| | C10 | Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Eng J Med. 2001;345:747-755 | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 9/27/06 |
|--------------------|---|-----------------|---------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|--------------------------|---------------------|------------------------|----------------|
| Substitute for form 1449PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Application Number | 10/643,743 | | |
| | | Filing Date | August 19, 2003 | | |
| | | First Named Inventor | Réal Lemieux et al. | | |
| | | Art Unit | 1645 | | |
| | | Examiner Name | Not yet known | | |
| Sheet | 3 | of | 4 | Attorney Docket Number | 701826--054340 |

| | | |
|----|-----|---|
| MS | C11 | Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun. 1999;13:129-135 |
| J | C12 | Kimberly RP, Salmon JE, Bussell JB, Crow MK, Hilgartner MW. Modulation of mononuclear phagocyte function by intravenous immunoglobulin. J Immunol. 1984;132:745-750 |
| ↓ | C13 | Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayoub A, Evelyne M, Coutinho A, Kazatchkine MD. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods. 1998;216:117-137 |
| MS | C14 | Larroche C, Chanseaud Y, Garcia de la Pena-Lefebvre P, Mouthon L. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders. Biodrugs. 2002;16:47-55 |
| J | C15 | Lazarus AH, Freedman J, Semple JW. Intravenous immunoglobulin and anti-D in idiopathic thrombocytopenia purpura (ITP): mechanisms of action. Transfus Sci. 1998;19:289-294 |
| J | C16 | Lock RJ, Unsworth DJ. Measurement of immune complexes is not useful in routine clinical practice. Ann Clin Biochem. 2000;37:253-261 |
| ↓ | C17 | Louzir H, Ternynck T, Gorgi Y, Ayed K, Avrameas S. Enzyme immunoassay analysis of antibody specificities present in the circulating immune complexes of selected pathological sera. J Immunol Methods. 1988;114:145-153 |
| MS | C18 | Matejtschuk P, Chidwick K, Prince A, More JE, Goldblatt E. A direct comparison of the antigen-specific antibody profiles of intravenous immunoglobulins derived from US and UK donors plasmas. Vox Sang. 2002;83:17-22 |
| J | C19 | Mizutani H, Engelman RW, Kurata Y, Ikehara S, Good RA. Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenia purpura-prone (NZW x BXSB) F1 mice. Blood. 1993;82:837-844 |
| J | C20 | Ohlson S, Zetterstrand K. Detection of circulating immune complexes by PEG precipitation combined with ELISA. J Immunol Methods. 1985;77:87-93 |
| ↓ | C21 | Rossi F, Guilbert B, Tonnelle C, Ternynck T, Fumoux F, Avrameas S, Kazatchkine MD. Idiotypic interactions between normal human polyspecific IgG and natural IgM antibodies. Eur J Immunol. 1990;20:2089-2094 |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 9/27/06 |
|--------------------|---|-----------------|---------|

*EXAMINER If reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

| | | | | | |
|---|---|----|--------------------------|------------------------|---------------|
| Substitute for form 1449PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/643,743 | |
| | | | Filing Date | August 19, 2003 | |
| | | | First Named Inventor | Réal Lemieux et al. | |
| | | | Art Unit | 1645 | |
| | | | Examiner Name | Not yet known | |
| Sheet | 4 | of | 4 | Attorney Docket Number | 701826-054340 |

| | | |
|-----|-----|--|
| 131 | C22 | Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science. 2001;291:484-486 |
| 131 | C23 | Theofilopoulos AN. The Raji, conglutinin, and anti-C3 assays for the detection of complement-fixing immune complexes. Methods Enzymol. 1981;74:511-530 |
| | C24 | Vassilev TL, Bineva IL, Dietrich G, Kaveri SV, Kazatchkine MD. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies. J Autoimmun. 1995;8:405-413 |
| | C25 | Vassilev TL et al., "Inhibition of cell adhesion by antibodies to Arg-Gly-Asp(RGD) in normal immunoglobulin for therapeutic use...". BLOOD, W. B. SAUNDERS COMPANY vol.93, no. 11, 1999, pages 3624-3631 |
| | C26 | Kaveri Srini et al. "Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in...". Journal of Clinical Investigation, vol. 97,, no.3, 1996, pages 865-869. |
| | | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 9/27/06 |
|--------------------|---|-----------------|---------|


*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Incomplete,
missing
pages



| | | | | | |
|---|---|----|--------------------------|------------------------|---------------|
| Substitute for form 1449 PTO | | | Complete if Known | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Application Number | 10/643,743 | |
| | | | Filing Date | 08/19/2003 | |
| | | | First Named Inventor | Lemieux. R. | |
| | | | Art Unit | 1645 | |
| | | | Examiner Name | To be assigned | |
| Sheet | 1 | of | 1 | Attorney Docket Number | 701826-054340 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|--|
| Examiner Initials* | Cite No. ¹ | Document Number Number - Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear |
| | | | | | |
| | | | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|--|------------|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear | T ² |
| | | Country Code3 - Number4 - Kind Code5 (if known) | | | | | |
| W | B2 | EP 1 059 088 A1 | 12-13-2000 | Bouvet et al | | | X |
| | | | | | | | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner Signature | | Date Considered | 9/27/06 |
|-----------------------|--|--------------------|---------|

*EXAMINER if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.